160 related articles for article (PubMed ID: 28879097)
1. Signatures derived from increase in SHARPIN gene copy number are associated with poor prognosis in patients with breast cancer.
Ojo D; Seliman M; Tang D
BBA Clin; 2017 Dec; 8():56-65. PubMed ID: 28879097
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of CYB5D2 is associated with breast cancer progression.
Ojo D; Rodriguez D; Wei F; Bane A; Tang D
Sci Rep; 2019 Apr; 9(1):6624. PubMed ID: 31036830
[TBL] [Abstract][Full Text] [Related]
3. A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.
Ojo D; Wu Y; Bane A; Tang D
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):735-745. PubMed ID: 29248549
[TBL] [Abstract][Full Text] [Related]
4. Elevation of SIPL1 (SHARPIN) Increases Breast Cancer Risk.
De Melo J; Tang D
PLoS One; 2015; 10(5):e0127546. PubMed ID: 25992689
[TBL] [Abstract][Full Text] [Related]
5. Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.
Tao Z; Li T; Feng Z; Liu C; Shao Y; Zhu M; Gong C; Wang B; Cao J; Wang L; Du Y; Lizaso A; Li B; Zhang J; Hu X
Front Oncol; 2020; 10():1023. PubMed ID: 32695676
[No Abstract] [Full Text] [Related]
6. High expression of the vacuole membrane protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer.
Amirfallah A; Arason A; Einarsson H; Gudmundsdottir ET; Freysteinsdottir ES; Olafsdottir KA; Johannsson OT; Agnarsson BA; Barkardottir RB; Reynisdottir I
PLoS One; 2019; 14(8):e0221413. PubMed ID: 31442252
[TBL] [Abstract][Full Text] [Related]
7. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
[TBL] [Abstract][Full Text] [Related]
8. High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer.
Takeshita T; Asaoka M; Katsuta E; Photiadis SJ; Narayanan S; Yan L; Takabe K
Am J Transl Res; 2019; 11(10):6507-6521. PubMed ID: 31737202
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
10. Genomic Characterization of Aggressive Breast Cancer in Younger Women.
Franco I; Alshalalfa M; Hernandez A; Mahal BA; Nguyen T; Wang L; Punglia R; Swami N; Goel N
Ann Surg Oncol; 2023 Nov; 30(12):7569-7578. PubMed ID: 37550448
[TBL] [Abstract][Full Text] [Related]
11. SHARPIN stabilizes estrogen receptor α and promotes breast cancer cell proliferation.
Zhuang T; Yu S; Zhang L; Yang H; Li X; Hou Y; Liu Z; Shi Y; Wang W; Yu N; Li A; Li X; Li X; Niu G; Xu J; Hasni MS; Mu K; Wang H; Zhu J
Oncotarget; 2017 Sep; 8(44):77137-77151. PubMed ID: 29100376
[TBL] [Abstract][Full Text] [Related]
12. Identification of the key pathways and genes involved in HER2-positive breast cancer with brain metastasis.
Lu X; Gao C; Liu C; Zhuang J; Su P; Li H; Wang X; Sun C
Pathol Res Pract; 2019 Aug; 215(8):152475. PubMed ID: 31178227
[TBL] [Abstract][Full Text] [Related]
13. Risk Signature of Cancer-Associated Fibroblast-Secreted Cytokines Associates With Clinical Outcomes of Breast Cancer.
Sun C; Wang S; Zhang Y; Yang F; Zeng T; Meng F; Yang M; Yang Y; Hua Y; Fu Z; Li J; Huang X; Wu H; Yin Y; Li W
Front Oncol; 2021; 11():628677. PubMed ID: 34395236
[TBL] [Abstract][Full Text] [Related]
14. Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics.
Li CY; Xiong DD; Huang CQ; He RQ; Liang HW; Pan DH; Wang HL; Wang YW; Zhu HW; Chen G
Med Sci Monit; 2017 Apr; 23():1857-1871. PubMed ID: 28416776
[TBL] [Abstract][Full Text] [Related]
15. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D
Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519
[TBL] [Abstract][Full Text] [Related]
16. Taxifolin Inhibits Breast Cancer Growth by Facilitating CD8+ T Cell Infiltration and Inducing a Novel Set of Genes including Potential Tumor Suppressor Genes in 1q21.3.
Lin X; Dong Y; Gu Y; Kapoor A; Peng J; Su Y; Wei F; Wang Y; Yang C; Gill A; Neira SV; Tang D
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370814
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide screen identifies a novel prognostic signature for breast cancer survival.
Mao XY; Lee MJ; Zhu J; Zhu C; Law SM; Snijders AM
Oncotarget; 2017 Feb; 8(8):14003-14016. PubMed ID: 28122328
[TBL] [Abstract][Full Text] [Related]
18. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
19. Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers.
O'Meara T; Marczyk M; Qing T; Yaghoobi V; Blenman K; Cole K; Pelekanou V; Rimm DL; Pusztai L
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923897
[TBL] [Abstract][Full Text] [Related]
20. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
